MDX-CTLA4 [ipilimumab] combined with IL-2 for patients with metastatic melanoma

Trial Profile

MDX-CTLA4 [ipilimumab] combined with IL-2 for patients with metastatic melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2013

At a glance

  • Drugs Ipilimumab (Primary) ; Interleukin-2
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top